Compare iShares 7-10 Year Treasury Bond ETF (IEF) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 7-10 Year Treasury Bond ETF vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? iShares 7-10 Year Treasury Bond ETF trades at $90.38 (market cap $41.29B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: iShares 7-10 Year Treasury Bond ETF is far larger — about 42.2× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares 7-10 Year Treasury Bond ETF for 108 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| IEF | MRVI | |
|---|---|---|
Market Cap | $41.29B | $977.37M |
Volume | 11,588,563 | 2,742,564 |
Sector | Fixed Income | Health |
52-Week High | $97.99 | $9.00 |
52-Week Low | $88.92 | $2.83 |
Typical Hold Time | 108 Days | 0 Days |
Enterprise Value | — | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEF trades at $89.54 with minimal daily movement (+0.12%), showing stability amid broader bond market volatility. Technical indicators signal a bearish trend with moving averages and oscillators in sell territory, while recent dividend distributions provide income stability. The bond ETF faces headwinds from rising Treasury yields and inflationary pressures, though recent yield retreats offer some relief.
The outlook remains cautious as IEF navigates persistent bond market pressures. While dividend payments offer income appeal, the bearish technical setup and macroeconomic uncertainty suggest limited near-term upside. Key risks include continued yield increases and inflationary pressures that could further pressure bond prices.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
